Celltrion's 'Remsima SC', "Praised at the European Rheumatology Congress"

[Asia Economy Reporter Chunhee Lee] Celltrion's world-first infliximab subcutaneous (SC) injection bio-better, 'RemsimaSC,' received high praise from local medical professionals at the 2022 European League Against Rheumatism (EULAR), emphasizing its therapeutic effects.

On the 3rd, Celltrion Group held an academic symposium on the 2nd (local time) at the Bella Center in Copenhagen, Denmark, under the theme "From Intravenous (IV) to SC: Will It Be a New Opportunity?"

EULAR is one of the most prestigious academic societies in the field of rheumatic diseases, where the latest clinical research and trends in therapeutic development are presented. This year's conference is held both online and offline from June 1 to 4 in Copenhagen.

At this symposium, over 200 participants including rheumatology specialists and industry stakeholders shared the latest information on the therapeutic efficacy of the infliximab SC formulation and the switching treatment effects from infliximab IV to SC.

In particular, the phase 3 clinical trial results of RemsimaSC showed non-inferiority in drug efficacy and safety evaluations compared to the RemsimaIV patient group, confirming that treatment efficiency can be maintained. This result received high praise from the attending medical professionals at the symposium.

Paul Emery, a leading key opinion leader (KOL) in the rheumatology field and a professor at the University of Leeds, UK, who presented at the symposium, stated, "RemsimaSC is the first SC formulation of infliximab and is emerging as a new treatment option in the autoimmune disease treatment market. Clinical data have proven the value of RemsimaSC as a bio-better, and we expect it to provide medical benefits to more patients."

RemsimaSC is a bio-better product developed as an SC formulation of infliximab, which is widely used in the TNF-α (tumor necrosis factor) inhibitor market. It has completed patent applications for formulation and administration methods in about 130 countries worldwide, securing exclusive rights for approximately 20 years. Recently, RemsimaSC prescriptions have been rapidly increasing in Europe due to its fast administration effect and formulation convenience.

Celltrion is currently conducting phase 3 clinical trials aiming for RemsimaSC's entry into the U.S. market next year. Based on Remsima's expanding market share in the U.S. and growth track in Europe, the company plans to do its best to facilitate rapid switching to RemsimaSC in the future.

This content was produced with the assistance of AI translation services.